Skip to content
Benoxinate
Altafluor Benox (benoxinate) is a small molecule pharmaceutical. Benoxinate was first approved as Benoxinate hydrochloride on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Altafluor benox
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Benoxinate hydrochloride
+
Fluorescein sodium
Tradename
Company
Number
Date
Products
ALTAFLUOR BENOXAltaire PharmaceuticalsN-208582 RX2017-12-14
1 products, RLD, RS
FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDEBausch Health CompaniesN-211039 RX2020-03-09
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
fluorescein sodium and benoxinate hydrochlorideNDA authorized generic2023-03-16
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Benoxinate Hydrochloride / Fluorescein Sodium, Fluorescein Sodium And Benoxinate Hydrochloride, Bausch Lomb Ireland
102930472037-11-15DPU-2755
106321972037-11-15DPU-2755
108428722037-11-15U-3001
ATC Codes
D: Dermatologicals
D04: Antipruritics, incl. antihistamines, anesthetics, etc.
D04A: Antipruritics, incl. antihistamines, anesthetics, etc.
D04AB: Anesthetics for topical use
D04AB03: Oxybuprocaine
S: Sensory organ drugs
S01: Ophthalmologicals
S01H: Local anesthetics, ophthalmologic
S01HA: Local anesthetics
S01HA02: Oxybuprocaine
HCPCS
No data
Clinical
Clinical Trials
92 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382U07.1129214
Diabetes mellitusD003920EFO_0000400E08-E13112
Drug-related side effects and adverse reactionsD064420T88.711
Autonomic nervous system diseasesD001342EFO_0009532G9011
Coronavirus infectionsD018352EFO_0007224B34.211
CoronavirusD01793411
Coronary diseaseD00332711
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.911
Virus diseasesD014777B3411
Whooping coughD014917EFO_0000650A3711
Show 4 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Urinary bladder neoplasmsD001749C672101122
TuberculosisD014376EFO_0000774A15-A19841113
Urologic neoplasmsD014571C64-C681134
Healthy volunteers/patients213
Colorectal neoplasmsD0151792213
Mycobacterium bovisD009163NCBITaxon_176522
NeoplasmsD009369C8022
Urologic diseasesD014570N39.922
Neoplasms by siteD00937122
Urinary bladder diseasesD001745N32.922
Show 6 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MelanomaD008545112
Type 1 diabetes mellitusD003922EFO_0001359E1022
Cognitive dysfunctionD060825G31.84112
Hiv infectionsD015658EFO_0000764B20122
Ovarian neoplasmsD010051EFO_0003893C5611
FibromyalgiaD005356EFO_0005687M79.111
HivD006678O98.711
Cystic fibrosisD003550EFO_0000390E8411
BronchiectasisD001987HP_0002110J4711
Nontuberculous mycobacteriaD00917011
Show 3 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C5011
Transitional cell carcinomaD00229511
SarcomaD01250911
NeuroblastomaD009447EFO_000062111
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Innate immunityD00711322
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBENOXINATE
INNoxybuprocaine
Description
Oxybuprocaine is a benzoate ester in which 4-amino-3-butoxybenzoic acid and 2-(diethylamino)ethanol have combined to form the ester bond; an ester-based local anaesthetic (ester "caine") used especially in ophthalmology and otolaryngology. It has a role as a local anaesthetic, a topical anaesthetic and a drug allergen. It is a benzoate ester, a tertiary amino compound, a substituted aniline and an amino acid ester. It is functionally related to a 2-diethylaminoethanol.
Classification
Small molecule
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCOc1cc(C(=O)OCCN(CC)CC)ccc1N
Identifiers
PDB
CAS-ID99-43-4
RxCUI18889
ChEMBL IDCHEMBL1200
ChEBI ID309594
PubChem CID4633
DrugBankDB00892
UNII IDAXQ0JYM303 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,064 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
648 adverse events reported
View more details